Table 1.
Demographic and disease characteristics of patients with ulcerative colitis by bowel urgency status and treatment experience.
| TT-naïve | 1L-TT | TT-exp | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | No BU (n = 457) |
BU (n = 138) |
P-value | No BU (n = 708) |
BU (n = 143) |
P-value | No BU (n = 238) |
BU (n = 83) |
P-value |
| Physician-reported | |||||||||
| Age, mean (SD) | 40.9 (14.6) | 37.8 (13.9) | .028 (t-test) | 40.3 (13.9) | 43.0 (14.5) | .037 (t-test) | 43.5 (14.7) | 42.7 (13.4) | .649 (t-test) |
| Sex, male, n (%) | 264 (57.8) | 67 (48.6) | .063 (FE) | 396 (55.9) | 71 (49.7) | .197 (FE) | 118 (49.6) | 46 (55.4) | .375 (FE) |
| BMI, mean (SD) | 24.2 (3.4) | 23.2 (3.0) | .003 (t-test) | 24.7 (3.7) | 24.9 (4.4) | .499 (t-test) | 24.3 (3.9) | 24.6 (4.5) | .557 (t-test) |
| Smoking status, n | 424 | 133 | .001 (CH) | 667 | 136 | .067 (CH) | 228 | 75 | .515 (CH) |
| Current smoker, n (%) | 72 (17.0) | 35 (26.3) | 79 (11.8) | 19 (14.0) | 24 (10.5) | 5 (6.7) | |||
| Ex-smoker, n (%) | 108 (25.5) | 45 (33.8) | 193 (28.9) | 51 (37.5) | 78 (34.2) | 24 (32.0) | |||
| Never smoked, n (%) | 244 (57.5) | 53 (39.8) | 395 (59.2) | 66 (48.5) | 126 (55.3) | 46 (61.3) | |||
| Employment status, n | 436 | 137 | <.001 (CH) | 684 | 140 | .601 (CH) | 231 | 78 | .896 (CH) |
| Working full-time, n (%) | 284 (65.1) | 68 (49.6) | 400 (58.5) | 72 (51.4) | 125 (54.1) | 43 (55.1) | |||
| Working part-time, n (%) | 32 (7.3) | 26 (19.0) | 84 (12.3) | 18 (12.9) | 29 (12.6) | 12 (15.4) | |||
| On long-term sick leave, n (%) | 6 (1.4) | 1 (0.7) | 11 (1.6) | 3 (2.1) | 12 (5.2) | 4 (5.1) | |||
| Homemaker, n (%) | 22 (5.0) | 9 (6.6) | 44 (6.4) | 13 (9.3) | 20 (8.7) | 7 (9.0) | |||
| Student, n (%) | 41 (9.4) | 21 (15.3) | 64 (9.4) | 13 (9.3) | 14 (6.1) | 3 (3.8) | |||
| Retired, n (%) | 37 (8.5) | 7 (5.1) | 53 (7.7) | 16 (11.4) | 26 (11.3) | 6 (7.7) | |||
| Unemployed, n (%) | 14 (3.2) | 5 (3.6) | 28 (4.1) | 5 (3.6) | 5 (2.2) | 3 (3.9) | |||
| Duration of IBD, n | 399 | 122 | .505 (t-test) | 661 | 131 | .204 (t-test) | 220 | 72 | .731 (t-test) |
| Duration of IBD, years, mean (SD) | 4.8 (6.5) | 4.4 (6.0) | 4.8 (5.5) | 5.5 (6.0) | 7.8 (5.9) | 7.5 (5.4) | |||
| Current severity, n | 457 | 138 | <.001 (MW) | 708 | 143 | <.001 (MW) | 238 | 83 | <.001 (MW) |
| Mild, n (%) | 377 (82.5) | 78 (56.5) | 565 (79.8) | 72 (50.3) | 179 (75.2) | 39 (47.0) | |||
| Moderate/severe, n (%) | 80 (17.5) | 60 (43.5) | 143 (20.2) | 71 (49.7) | 59 (24.8) | 44 (53.0) | |||
| Current remission status, n | 457 | 138 | <.001 (MW) | 708 | 143 | <.001 (MW) | 238 | 83 | <.001 (MW) |
| In remission, n (%) | 324 (70.9) | 42 (30.4) | 498 (70.3) | 41 (28.7) | 159 (66.8) | 17 (20.5) | |||
| Current flaring status, n | 411 | 129 | <.001 (FE) | 670 | 137 | <.001 (FE) | 224 | 81 | <.001 (FE) |
| Flaring, n (%) | 26 (6.3) | 24 (18.6) | 39 (5.8) | 25 (18.2) | 15 (6.7) | 26 (32.1) | |||
| Current steroid use, n | 457 | 138 | <.001 (FE) | 708 | 143 | .002 (FE) | 238 | 83 | .016 (FE) |
| Receiving steroids, n (%) | 87 (19.0) | 59 (42.8) | 27 (3.8) | 15 (10.5) | 17 (7.1) | 14 (16.9) | |||
| HCP visits, n | 456 | 138 | .001 (t-test) | 699 | 143 | <.001 (t-test) | 238 | 83 | .185 (t-test) |
| HCP visits in past year, mean (SD) | 3.9 (3.2) | 5.0 (4.2) | 5.7 (4.5) | 7.2 (6.8) | 7.4 (6.6) | 6.4 (4.1) | |||
| Patient-reported | |||||||||
| EQ VAS, n | 151 | 53 | .007 (t-test) | 209 | 52 | <.001 (t-test) | 65 | 24 | .001 (t-test) |
| EQ VAS, mean (SD) | 80.8 (11.8) | 75.2 (15.5) | 84.1 (14.8) | 75.8 (16.8) | 80.0 (15.4) | 67.3 (17.6) | |||
| WPAI, n | 75 | 32 | <.001 (t-test) | 108 | 28 | .039 (t-test) | 38 | 15 | .004 (t-test) |
| Overall work impairment, mean (SD) % | 15.0 (19.5) | 33.7 (26.5) | 13.7 (20.9) | 22.9 (20.5) | 14.1 (16.0) | 32.1 (26.7) | |||
| SIBDQ, n | 149 | 51 | .004 (t-test) | 201 | 52 | <.001 (t-test) | 64 | 24 | .003 (t-test) |
| SIBDQ total score, mean (SD) | 56.1 (11.5) | 50.8 (10.1) | 57.7 (11.0) | 49.7 (10.7) | 56.0 (12.4) | 46.8 (14.0) | |||
Abbreviations: BMI, body mass index; BU, bowel urgency; CH, χ2 test; EQ VAS, EuroQol visual analog scale; FE, Fisher’s exact test; HCP, healthcare practitioner; IBD, inflammatory bowel disease; MW, Mann–Whitney test; SD, standard deviation; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; TT-naïve, patients who were currently receiving conventional therapy with a duration >3 months and had never received targeted therapy; 1L-TT, patients who were currently receiving their first targeted therapy with a duration >3 months; TT-exp, patients who were currently receiving their second or later targeted therapy with duration >3 months; WPAI, work productivity and activity impairment.